MRTX — Mirati Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.12bn
- $3.15bn
- $12.44m
Street View: Mirati's lung cancer drug to face tough competition from Amgen
U.S. STOCKS ON THE MOVE-Alphabet, Moderna, chip stocks
U.S. STOCKS ON THE MOVE-Eli Lilly, Payment firms, Big tech
Mirati jumps after FDA approves lung cancer drug
U.S. RESEARCH ROUNDUP- Amgen, Coupa Software, Zebra Technologies
Brief: Mirati Therapeutics Announces U.S. FDA Accelerated Approval Of Krazati™ As A Targeted Treatment Option For Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer With A Krasg12c Mutation
Mirati Therapeutics gains on FDA approval for lung cancer drug
U.S. FDA approves Mirati's lung cancer drug (updated)
U.S. FDA approves Mirati's lung cancer drug
Mirati slips as brokerages bearish on experimental cancer drug data
U.S. RESEARCH ROUNDUP- Churchill Downs, Mirati Therapeutics, Vivint Smart Home
U.S. STOCKS ON THE MOVE-Moderna, crypto stocks, U.S. banks
Mirati slumps as data on experimental cancer drug disappoints
U.S. STOCKS ON THE MOVE-Gossamer Bio, Summit Therapeutics, VistaGen
U.S. STOCKS ON THE MOVE-JPMorgan, Textron, Gold miners
Mirati to focus on drug combination study in low PDL1 lung cancer patients
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients (updated)
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
U.S. STOCKS ON THE MOVE-Aurora, Boeing, Lockheed Martin